Phase 1 study of the oral platinum agent satraplatin in combination with capecitabine for the treatment of patients with advanced solid malignancies.

Trial Profile

Phase 1 study of the oral platinum agent satraplatin in combination with capecitabine for the treatment of patients with advanced solid malignancies.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 27 Mar 2012

At a glance

  • Drugs Capecitabine; Satraplatin
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Agennix AG
  • Most Recent Events

    • 27 Mar 2012 Inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.
    • 21 Mar 2012 Agennix as trial company and lead trial centre added as reported by ClinicalTrials.gov.
    • 21 Mar 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top